You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Article info

Article menu
Basic tumor immunology
Original research
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Authors

  • Nicola Principe Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaSchool of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Amber-Lee Phung Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Kofi L P Stevens Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Omar Elaskalani Telethon Kids Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Ben Wylie Telethon Kids Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Caitlin M Tilsed Perelman School of Medicine, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Fezaan Sheikh Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaSchool of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • M Lizeth Orozco Morales Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaTelethon Kids Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Joel Kidman Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaSchool of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Elly Marcq Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerpen, BelgiumBrussels Center for Immunology, Vrije Universiteit Brussel, Brussels, BelgiumLab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium PubMed articlesGoogle scholar articles
  • Scott A Fisher Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaSchool of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Anna K Nowak Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaMedical School, The University of Western Australia, Crawley, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Alison M McDonnell Telethon Kids Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • W Joost Lesterhuis Telethon Kids Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Jonathan Chee Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, AustraliaSchool of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jonathan Chee; jonathan.chee{at}uwa.edu.au
View Full Text

Citation

Principe N, Phung A, Stevens KLP, et al
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade
Journal for ImmunoTherapy of Cancer 2024;12:e008568. doi: 10.1136/jitc-2023-008568

Publication history

  • Accepted September 8, 2024
  • First published September 28, 2024.
Online issue publication 
September 28, 2024

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.